Abstract:Background: Immunotherapy has revolutionized the therapeutical regimen for nasopharyngeal carcinoma (NPC), yet its response rate remains insufficient. Programmed death-ligand 1 (PD-L1) on small extracellular vesicles (sEVs) mediates local and peripheral immunosuppression in tumors, and the mechanism of PD-L1 loading into these vesicles is garnering increasing attention. Latent membrane protein 1 (LMP1), a key viral oncoprotein expressed in Epstein-Barr virus (EBV)-positive NPC, contributes to remodeling the tumor microenvironment. However, the precise mechanisms by which LMP1 modulates tumor immunity in NPC remain unclear. Here, we aimed to investigate the roles and regulatory mechanisms of LMP1 and sEV PD-L1 in NPC immune evasion. Methods: We analyzed the impact of LMP1 on tumor-infiltrating lymphocyte abundance in NPC tissues and humanized tumor-bearing mouse models using multiplex immunofluorescence (mIF) and flow cytometry, respectively. Transmission electron microscopy and nanoparticle tracking analysis were employed to characterize sEVs. Immunoprecipitation-mass spectrometry was utilized to identify proteins interacting with LMP1. The regulatory effects of sEVs on tumor microenvironment were assessed by monitoring CD8+ T cell proliferation and interferon-γ (IFN-γ) expression via flow cytometry. Furthermore, the expression patterns of LMP1 and downstream regulators in NPC were analyzed using mIF and survival analysis. Results: High LMP1 expression in NPC patient specimens and mouse models was associated with restricted infiltration of CD8+ T cells. Additionally, LMP1 promoted sEV PD-L1 secretion, leading to inhibition of CD8+ T cell viability and IFN-γ expression in vitro. Mechanistically, LMP1 recruited apoptosis-linked gene 2-interacting protein X (ALIX) through its intracellular domain and bound PD-L1 through its transmembrane domain, thereby facilitating the loading of PD-L1 into ALIX-dependent sEVs. Disruption of ALIX diminished LMP1-induced sEV PD-L1 secretion and enhanced the anti-tumor immunity of CD8+ T cells both in vitro and in vivo. Moreover, increased expression levels of LMP1 and ALIX were positively correlated with enhanced immunosuppressive features and worse prognostic outcomes in NPC patients. Conclusion: Our findings uncovered the mechanism by which LMP1 interacts with ALIX and PD-L1 to form a trimolecular complex, facilitating PD-L1 loading into ALIX-dependent sEV secretion pathway, ultimately inhibiting the anti-tumor immune response in NPC. This highlights a novel target and prognostic marker for NPC immunotherapy.

Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Promotes Extracellular Vesicle Secretion Through Syndecan-2 and Synaptotagmin-Like-4 in Nasopharyngeal Carcinoma Cells

Extracellular Vesicle Packaged LMP1-activated Fibroblasts Promote Tumor Progression Via Autophagy and Stroma-Tumor Metabolism Coupling.

Role of Epstein-Barr Virus Encoded Latent Membrane Protein 1 in the Carcinogenesis of Nasopharyngeal Carcinoma.

Epstein-Barr Virus-Encoded LMP2A Induces an Epithelial-Mesenchymal Transition and Increases the Number of Side Population Stem-Like Cancer Cells in Nasopharyngeal Carcinoma.

EBV Latent Membrane Proteins Promote Hybrid Epithelial-Mesenchymal and Extreme Mesenchymal States of Nasopharyngeal Carcinoma Cells for Tumorigenicity.

Regulation of Survivin and CDK4 by Epstein-Barr Virus Encoded Latent Membrane Protein 1 in Nasopharyngeal Carcinoma Cell Lines

The Epstein-Barr Virus Encoded Latent Membrane Protein 1 Promotes Nuclear Factor-kappa B Activity in a Nasopharyngeal Carcinoma Cell Line

LMP1-positive extracellular vesicles promote radioresistance in nasopharyngeal carcinoma cells through P38 MAPK signaling

Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma

Targeting the LMP1-ALIX axis in EBV+ nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti-tumor immunity

Epstein-Barr Virus Encoded LMP1 Regulates Cyclin D1 Promoter Activity by Nuclear EGFR and STAT3 in CNE1 Cells

Epstein-Barr Virus Induces Lymphangiogenesis and Lympth Node Metastasis via Upregulation of VEGF-C in Nasopharyngeal Carcinoma

Epstein-Barr Virus Encoded Latent Membrane Protein 1 Regulates Mtor Signaling Pathway Genes Which Predict Poor Prognosis of Nasopharyngeal Carcinoma

Epstein-Barr viral product-containing exosome facilitates LIF-associated immunosuppressive polarization of macrophage in nasopharyngeal carcinoma

Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma.

Tyrosylprotein Sulfotransferase-1 And Tyrosine Sulfation Of Chemokine Receptor 4 Are Induced By Epstein-Barr Virus Encoded Latent Membrane Protein 1 And Associated With The Metastatic Potential Of Human Nasopharyngeal Carcinoma

EB Virus Encoded Latent Membrane Protein 1 Mediated Expression of Transcription Factor Ets-1 in Nasopharyngeal Carcinoma Cells

Nuclear Accumulation of Epidermal Growth Factor Receptor and Acceleration of G1/S Stage by Epstein–Barr-encoded Oncoprotein Latent Membrane Protein 1

EBV‑LMP1 is Involved in Vasculogenic Mimicry Formation Via VEGFA/VEGFR1 Signaling in Nasopharyngeal Carcinoma.

LMP1-mediated Glycolysis Induces Myeloid-Derived Suppressor Cell Expansion in Nasopharyngeal Carcinoma

Nuclear Translocation of EGF Receptor Regulated by Epstein-Barr Virus Encoded Latent Membrane Protein 1